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Until the end of the past millenium, relatively little attention was
given to control of blood sugar levels. In critically ill patients,
hyperglycaemia was considered to be physiological because it
results from the metabolic and hormonal changes that
accompany the stress response to injury. In most intensive care
units (ICUs), blood sugar was checked every 4–6 hours and
hyperglycaemia (defined as blood sugar levels >10–12 mmol/l
[180–216 mg/dl]) was corrected by subcutaneous or
intravenous insulin. The presence of pre-existing diabetes
mellitus or post-neurosurgical status often prompted more
intense control of hyperglycaemia. Furthermore, the issue of
glucose control was discussed in few sessions or satellite
symposia during intensive care meetings.
The deleterious effects of hyperglycaemia during critical
illness have been characterized over the past few years, and
include an increased susceptibility to infections and
thromboses, macrovascular and microvascular changes, and
delayed wound healing, among other effects (for review [1]).
Renewed interest in control of hyperglycaemia in critically ill
patients (Fig. 1) followed the publication of a study
conducted by Van den Berghe and coworkers in 2001 [2].
Those investigators reported a 43% decrease in relative
intensive care mortality as well as consistent decreases in
several surrogate markers of disease severity in patients
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Abstract
The issue of tight glucose control with intensive insulin therapy in critically ill patients remains
controversial. Although compelling evidence supports this strategy in postoperative patients who have
undergone cardiac surgery, the use of tight glucose control has been challenged in other situations,
including in medical critically ill patients and in those who have undergone non-cardiac surgery.
Similarly, the mechanisms that underlie the effects of high-dose insulin are not fully elucidated. These
arguments emphasize the need to study the effects of tight glucose control in a large heterogeneous
cohort of intensive care unit patients.
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randomly assigned to tight glucose control by intensive
intravenous insulin therapy. A post hoc multivariate logistic
regression analysis of these data suggested that control of
hyperglycaemia played a more important role than did the
amount of insulin administered [3]. Interestingly enough, at
least two recent retrospective, large-scale studies [4,5]
confirmed that outcome was improved in patients whose
average blood glucose was maintained below 8 mmol/l
(144 mg/dl; Table 1).
Although the findings reported by Van den Berghe and
coworkers are impressive, some concern arose regarding the
applicability of these results to other types of patients. Of the
patients studied, 63% were admitted for follow up after
cardiac surgery; this high proportion was felt to be consistent
with a particular benefit from tight glucose control with
intensive insulin in these patients, but there is uncertainty
regarding whether tight glucose control is beneficial in
patients who have not undergone cardiac surgery. Fear of
life-threatening hypoglycaemia and increased workload and
costs probably underlie the reluctance of many intensivists to
launch systematic protocols of tight glucose control. Indeed,
many intensivists still use a high glucose threshold
(10 mmol/l [180 mg/dl]) [6]. In a European survey
(unpublished data) we found considerable variation in the
glycaemic thresholds employed in ICUs, which ranged from
6 to 11.1 mmol/l (108–200 mg/dl).
Some arguments against generalized use of tight glucose
control are reported in the present issue of Critical Care by
Vriesendorp and coworkers [7]. In a retrospective study
performed at one centre in Amsterdam, those authors found
that, after oesophageal surgery in patients without significant
cardiovascular compromise (ASA class I–II), postoperative
hyperglycaemia was not a risk factor for infectious
complications. Only by univariate analysis were they able to
find an improvement in patients with blood glucose levels
below 9.3 mmol/l (167 mg/dl) in terms of length of ICU stay.
These findings differ strikingly from those of other studies
[2,4,5]. Although the report by Vriesendorp and coworkers
challenges the concept of tight glucose control, it can hardly
be considered a major piece of evidence against it. Indeed,
blood glucose concentrations were presented as means of
values recorded only over 48 hours, whereas the ICU stay
extended up to 71 days, with a median of 3 days. Insulin was
administered to only 9% of the patients during the 48-hour
period of observation. In addition, patients received a mean
of only 22.5 g glucose/day, and were fed early after surgery
with an enteral solution of ‘immunonutrients’ – a potential
confounding factor with respect to infectious morbidity.
Table 1
Features of recent studies of glucose control in intensive care units
Reference
[2] [4] [5] [7]
Design Prospective, Retrospective,  Retrospective,  Retrospective, 
interventional observational observational observational
Target glucose levels (mmol/l)
Intervention 4.4–6.1 <8.0 4.4–7.8
Control 10.0–11.1 Not available 10.0–11.1 >12.0
Types of admission (n)
Surgical 1548 462 573 160
Medical 0 61 1027 0
Cardiac surgery (% of total) 63 85 0 0
Median APACHE II score 9 16 16 Not available
ICU mortality (%)
Intervention 4.6 Not available 14.8 3.3
Control 8.0 20.9
Primary end-points ICU mortality ICU mortality ICU mortality Infection rate, 
length of hospital stay
Secondary end-points In-hospital mortality, organ  Organ dysfunction, 
dysfunction, tranfusion rate,  transfusion rate, length 
critical illness polyneuropathy,  of ICU stay, infection 
infection rate rate
APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit.429
However, despite these limitations, as well as others that are
acknowledged by the authors, the findings of the study
support the hypothesis that tight glucose control could be of
greater benefit to patients with cardiovascular disease than
to those without.
In conclusion, as recently suggested by Van den Berghe [8],
further studies are needed to confirm the benefits of tight
blood glucose control with intensive insulin therapy in a
heterogeneous population of ICU patients. Hence, a large
randomized prospective multicentre trial is warranted. Such
study will also help in determining the physiological
importance of the effects of insulin and, more importantly, will
provide intensive care workers with key information for
guiding the management of blood glucose in critically ill
patients.
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